Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic HBV carriers~* biopsy proven chronic hepatitis~* active HBV replication for \> 6 months~* non responding to Interferon-alpha or lamivudine treatment~Exclusion Criteria:~* co-infection with HIV, HCV, delta hepatitis virus~* alcohol consumption\> 40g/day~* decompensated liver disease~* HLA DR2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- intramuscular injections (Type: EXPERIMENTAL): Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10

Based on this trial design, predict the completion outcome and termination type (if applicable).